To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter includes the diagnosis of T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) and measurable disease detection (MRD) post therapy. Flow cytometry immunophenotyping is essential in establishing a diagnosis of T-ALL/LBL and subclassifying by their maturation into early T-phenotype (ETP), near ETP, cortical thymic T-, and mature T-ALL/LBL. Recent advancement in genetic classifications of T-ALL/LBL shows high-risk genetic alterations are highly associated with ETP-ALL. T-ALL/LBL show overlap features with acute undifferentiated leukemia, mixed phenotype T/myeloid, T/B leukemia, indolent T-lymphoblastic proliferation, and mature T-cell lymphoma/leukemia. The features pertinent for differential diagnosis are illustrated. For MRD, the discussion includes the principles and strategies, analysis and interpretations, mimics and common pitfalls. The pros and cons of flow cytometry MRD are compared with molecular MRD, including NGS sequencing (Clonoseq). Although currently there is no FDA-approved CAR T-therapy for T-ALL, promising products such as CD7-CAR and CD5-CAR have been used in clinical trials. Strategies in MRD and challenges in the era of targeted therapy are discussed.
Acute undifferentiated leukemia (AUL) is part of the group of acute leukemias of ambiguous lineage (ALAL). It is characterized by the expression of immature hematopoietic cell markers but lacks the expression of markers that allow assignment to myeloid or lymphoid lineage. This chapter discusses the immunophenotype and molecular features of AUL and highlights the immunophenotypic features that can help in the differential diagnosis from other entities, including AML with minimal differentiation, AML with megakaryocytic or erythroid differentiation, T-lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, and rarely, non-hematopoietic neoplasms.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.